Clinical value of combined determination of TU M2-PK,TPS,CEA in the patients with lung cancer

Objective:To investigate the clinical value of serum TPS,CEA and plasma TU M2-PK in lung cancer patients.Methods:The concentration of TPS,CEA and TU M2-PK were detected by ELISA in 60 lung cancer patients,54 benign lung disease patients and 40 healthy people.Moreover follow-up visit was undertaken at one month and three months after surgery for lung cancer patients.Results:The level of TPS,CEA and TU M2-PK were significantly higher in lung cancer than those in benign lung disease and health controls(P0.05).TPS showed the highest sensitivity(78.3%) and TU M2-PK showed the highest accuracy(83.8%) in single tumor marker detection,and TU M2-PK+TPS+CEA showed the highest sensitivity(98.3%) and accuracy(89.0%),but lower specificity(83.0%) in combined tumor marker detection for diagnosis of lung cancer.The level of TPS,CEA,TU M2-PK in stage Ⅲ and stage Ⅳ were evidently higher than those in stage I,Ⅱ.After operation,a marked decreasing in these values was observed.Conclusion:There was specifically clinical application value of these three tumor markers for diagnosis and cure of lung cancer.The sensitivity and accuracy can be increased with combination of TU M2-PK+TPS+CEA in diagnosis of lung cancer.